Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ACE inhibitors in the elderly.

E L Posvar1, A J Sedman

  • 1Parke-Davis Pharmaceutical Research Division, Warner Lambert Company, Ann Arbor, Michigan.

Angiology
|May 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determining the wounding effects of ballistic projectiles to inform future injury models: a systematic review.

Journal of the Royal Army Medical Corps·2013
Same author

Clinafloxacin pharmacokinetics in subjects with various degrees of renal function.

Antimicrobial agents and chemotherapy·2001
Same author

Drug interactions with clinafloxacin.

Antimicrobial agents and chemotherapy·2001
Same author

Quinapril and its metabolite quinaprilat in human milk.

British journal of clinical pharmacology·2001
Same author

Single-dose gabapentin pharmacokinetics and safety in healthy infants and children.

Journal of clinical pharmacology·2001
Same author

Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol.

Contraception·2001
Same journal

Refining Phenotype-Based Interpretation of SGLT2 Inhibitors After AMI Without Heart Failure.

Angiology·2026
Same journal

Response to: "Integrating Noninvasive Liver Indices into Risk Stratification of Myocardial Infarction With Non-Obstructive Coronary Arteries".

Angiology·2026
Same journal

Response to: "Beyond Traditional Risk Markers: Is FIB-4 Sufficient in MINOCA?"

Angiology·2026
Same journal

Letter: Further Considerations on the Clinical Use of the Scottish Inflammatory Prognostic Score in STEMI No-Reflow Prediction.

Angiology·2026
Same journal

Contextualizing Remodeling Endpoints in Endovascular Treatment for Symptomatic SISMAD.

Angiology·2026
Same journal

<i>Response to the Letter to the Editor</i>: "Effect of Invasive Hemodynamic Monitoring on the Outcomes of Cardiogenic Shock in Patients With Acute Myocardial Infarction".

Angiology·2026
See all related articles

This review examines angiotensin-converting enzyme (ACE) inhibitors for hypertension in older adults. Quinapril demonstrated favorable tolerability across all age groups in clinical trials.

Area of Science:

  • Pharmacology
  • Geriatrics
  • Cardiovascular Medicine

Background:

  • Hypertension prevalence increases with age.
  • Understanding antihypertensive drug properties in the elderly is crucial.
  • Angiotensin-converting enzyme (ACE) inhibitors are a key treatment class.

Purpose of the Study:

  • To review the pharmacokinetics, efficacy, and safety of ACE inhibitors in young and elderly hypertensive patients.
  • To compare captopril, enalapril, and quinapril.
  • To assess the tolerability of these agents, particularly in older populations.

Main Methods:

  • Review of pharmacokinetic and efficacy data for captopril, enalapril, and quinapril.
  • Discussion of safety profiles in young and elderly patient cohorts.

Related Experiment Videos

  • Analysis of comparative clinical trial data.

    • Main Results:

    • Pharmacokinetics, efficacy, and safety data for captopril, enalapril, and quinapril were reviewed.
    • All three ACE inhibitors exhibited favorable safety profiles.
    • Quinapril showed a trend towards better tolerability in patients of all ages.

    Conclusions:

    • ACE inhibitors are important for managing hypertension in the elderly.
    • Quinapril appears to be well-tolerated across different age groups.
    • Further research may confirm quinapril's superior tolerability in hypertensive patients.